Serotype distribution among adults with community-acquired pneumococcal pneumonia in Japan between 2019 and 2022: A multicenter observational study
Authors:
Preprint
Abstract
Background: Streptococcus pneumoniae is a leading cause of community-acquired pneumonia in adults. With the introduction of pneumococcal conjugate vaccines (PCVs) into pediatric national immunization programs, the serotype distribution of pneumococcal disease among adults has changed due to herd immunity. In Japan, PCV15 and PCV20 have been introduced, and PCV21 has been under review for approval in adults. This study aimed to assess the distribution of pneumococcal serotypes among adults with pneumococcal pneumonia in Japan between May 2019 and December 2022. Methods: This multicenter observational study enrolled patients aged ≥18 years with community-acquired, culture-positive pneumococcal pneumonia from May 2019 to December 2022. Pneumococcal isolates were serotyped using the Quellung reaction, and proportions of individual and vaccine-covered serotypes were analyzed. Results: A total of 583 adult patients with pneumococcal pneumonia were included. The median age was 74 years (interquartile range: 66–82 years), 383 (65.7%) patients were male, and 387 (66.4%) patients had one or more underlying medical conditions. The most common serotypes were serotype 3 (12.5%), 35B (12.0%), 15A (7.7%), 11A (6.7%), and 23A (6.3%). The proportion of serotypes covered by PCV13, PCV15, PCV20, PPSV23, and PCV21 were 24.0, 28.0, 43.7, 44.1, and 71.9%, respectively. The proportions of vaccine-covered serotypes were similar between patients aged <65 and ≥65 years. Notably, serotype 3 was more prevalent among patients living in nursing homes (25.9%) compared with those living at home (11.2%). Conclusion: Serotypes 3 and 35B were the most common in adults with pneumococcal pneumonia in Japan during the study period. The proportions of PCV20- and PCV21-covered serotypes suggest that these new vaccines may offer additional protection against adult pneumococcal pneumonia. With the availability of newly developed PCVs for adults in Japan, it is time to reassess the optimal pneumococcal vaccination policy for adults.Keywords
All Related Versions
- Published version: Human Vaccines & Immunotherapeutics, 21 (1), 2518847.
This publication has 40 references indexed in Scilit:
- Pneumococcal serotypes and risk factors in adult community acquired pneumonia 2018–20: a multicentre UK cohort studyThe Lancet Regional Health - Europe, 2023
- Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020Vaccine, 2022
- Dynamic changes in clinical characteristics and serotype distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013–2019Vaccine, 2022
- National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017–2020Journal of Global Antimicrobial Resistance, 2021
- Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance DataInfectious Diseases and Therapy, 2021
- Burden of Community-Acquired Pneumonia and Unmet Clinical NeedsAdvances in Therapy, 2020
- Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumoniaVaccine, 2019
- Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literatureVaccine, 2017
- PCV13 serotype decrease in Italian adolescents and adults in the post-PCV13 era: Herd protection from children or secular trend?Vaccine, 2017
- Outbreaks of serious pneumococcal disease in closed settings in the post-antibiotic era: A systematic reviewJournal of Infection, 2010